New peptidomimetics in the chemistry of fibrinogen receptor antagonists

RGD-peptidomimetics are currently being investigated as a class of potential antithrombotics that antagonize the fibrinogen receptor, GP IIb/IIIa, on the surface of platelets. These mimetics are expected to have decisive advantages - such as higher activity and specificity, oral bioavailability and longer duration of action - over known antithrombotics. For further optimization in this respect, novel peptidomimetic CP IIb/IIIa antagonists with an oxazolidinonemethyl central building block were synthesized. This building block proved to be very versatile as an 'anchor' for structurally different C-termini and was the starting point for highly efficient and orally active compounds.